论文部分内容阅读
用免疫散射比浊法检测血清补体C_3共88例,其中肝硬化合并肝癌组20例,肝硬化组28例,另设正常对照组40例。结果发现,补体C_3含量肝硬化合并肝癌组(0.972±0.329g/L)与肝硬化组(0.604±0.177g/L)之间有极显著差异(P<0.001)。血清补体C_3含量以0.99g/L为界限,则补体C_3对肝硬化合并肝癌诊断的阳性预测值、阴性预测值、准确度分别为84.6%、74.2%、77.08%,当补体C_3与AFP联合检测时则分别上升为94.4%、90.0%、91.6%,且较r—GT与AFP联合诊断肝硬化合并肝癌的价值有所提高,进一步证实血清补体C_3可以作为诊断肝硬化合并肝癌的重要标志物。
Serum complement C_3 was detected by immunostaining turbidimetry in 88 cases, of which 20 cases were liver cirrhosis with hepatocellular carcinoma, 28 cases were liver cirrhosis and 40 cases were normal control group. The results showed that there was a significant difference (P <0.001) between complement C_3 content in liver cirrhosis with hepatocellular carcinoma (0.972 ± 0.329g / L) and liver cirrhosis (0.604 ± 0.177g / L). The positive predictive value, negative predictive value and the accuracy of complement C_3 for the diagnosis of cirrhosis with hepatocellular carcinoma were 84.6%, 74.2% and 77.08%, respectively, when the serum C_3 content was 0.99g / L. When complement C_3 and AFP were detected (94.4%, 90.0%, 91.6% respectively). The value of r-GT combined with AFP in the diagnosis of hepatocirrhosis complicated with hepatocellular carcinoma was further increased, further confirming that serum complement C 3 can be used as an important marker in diagnosing cirrhosis complicated with hepatocellular carcinoma.